Ligand id: 4985

Name: IL-2

Species: Human

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: interleukin-2

Immunopharmacology Comments
IL-2 participates in activation-induced cell death (AICD) and maintenance of peripheral CD4+CD25+ regulatory T (Treg) cells [2], two processes contributing towards the elimination of self-reactive T cells. Treg insufficiency is associated with autoimmune disease, and clinical evaluation of the effects of low dose IL-2 to promote Treg proliferation and function and combat immune inflammatory disorders is showing some promising results [3]. Current IL-2 therapy relies on recombinant peptide that is limited by a short half-life in vivo. To this end, drug developers are working to produce long-acting conjugates with improved pharmackokinetics. Examples include NKTR-358, a PEG-ylated IL-2 analogue that is being prepared for Phase 1 trial in patients with autoimmune conditions such as psoriasis, systemic lupus erythematosus (SLE), or others, and AMG392 (proposed INN efavaleukin alfa), which is an IL-2-IGHG1 Fc fusion protein being developed by Amgen. AMG392 is also designed to exhibit improved Treg selectivity compared to aldesleukin.
Immunopharmacology Disease
Disease X-Refs Comment References
non-Hodgkin lymphoma Disease Ontology: DOID:0060060
OMIM: 605027
US FDA orphan designation only, not approved for this indication.